Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;45(2):557-580.
doi: 10.1007/s12639-021-01387-w. Epub 2021 Apr 25.

A comprehensive and critical overview of schistosomiasis vaccine candidates

Aya Al-Naseri #  1 , Samar Al-Absi #  1 , Rashika El Ridi  1 , Noha Mahana  1
Affiliations
Review

A comprehensive and critical overview of schistosomiasis vaccine candidates

Aya Al-Naseri et al. J Parasit Dis. 2021 Jun.

Abstract

A digenetic platyhelminth Schistosoma is the causative agent of schistosomiasis, one of the neglected tropical diseases that affect humans and animals in numerous countries in the Middle East, sub-Saharan Africa, South America and China. Several control methods were used for prevention of infection or treatment of acute and chronic disease. Mass drug administration led to reduction in heavy-intensity infections and morbidity, but failed to decrease schistosomiasis prevalence and eliminate transmission, indicating the need to develop anti-schistosome vaccine to prevent infection and parasite transmission. This review summarizes the efficacy and protective capacity of available schistosomiasis vaccine candidates with some insights and future prospects.

Keywords: Candidate vaccines; Protective immunity; Schistosoma; Schistosomiasis; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestNo conflict of interest are declared by all authors.

Figures

Fig. 1
Fig. 1
Schistosome glucose transporter protein 4 structure (Skelly et al. 1998)
Fig. 2
Fig. 2
Multiple antigenic peptide structure
See this image and copyright information in PMC

References

    1. Abdel Aziz N, Tallima H, Abou El Dahab M, El Ridi R (2019) Immunogenicity and protective capacity of Schistosoma haematobium recombinant cathepsin L against infection of hamsters with S. haematobium. Vaccine Res 6:1–8. http://doi.vacres.pasteur.ac.ir/article-1-164-en.pdf
    1. Adekiya TA, Aruleba RT, Klein A, Fadaka AO. In silico inhibition of SGTP4 as a therapeutic target for the treatment of schistosomiasis. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1850363. - DOI - PubMed
    1. Affholter JA, Fried VA, Roth RA. Human insulin-degrading enzyme shares structural and functional homologies with Escherichia coli protease III. Science. 1988;242:1415–1418. doi: 10.1126/science.3059494. - DOI - PubMed
    1. Ahier A, Khayath N, Vicogne J, Dissous C. Insulin receptors and glucose uptake in the human parasite Schistosoma mansoni. Parasite. 2008;15:573–579. doi: 10.1051/parasite/2008154573. - DOI - PubMed
    1. Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Smp80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol. 2009;31:156–161. doi: 10.1111/j.1365-3024.2008.01091.x. - DOI - PMC - PubMed

LinkOut - more resources